Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H14N4O.ClH.3H2O |
| Molecular Weight | 356.805 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.Cl.O=C1CCC(=NN1)C2=CC=C(NC3=CC=NC=C3)C=C2
InChI
InChIKey=KQXCWCFBLZWIGE-UHFFFAOYSA-N
InChI=1S/C15H14N4O.ClH.3H2O/c20-15-6-5-14(18-19-15)11-1-3-12(4-2-11)17-13-7-9-16-10-8-13;;;;/h1-4,7-10H,5-6H2,(H,16,17)(H,19,20);1H;3*1H2
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The calcium sensitizer drug MCI-154 binds the structural C-terminal domain of cardiac troponin C. | 2018-12 |
|
| Inotropic therapy of heart failure. Editorial comments on: Vasodilation and mechanoenergetic inefficiency dominates the effect of the "Ca2+ sensitizer" MCI-154 in intact pigs. | 2002-05 |
|
| High selectivity for inhibition of phosphodiesterase III and positive inotropic effects of MCI-154 in guinea pig myocardium. | 1993-06 |
|
| Effects of MCI-154 on Ca2+ activation of skinned human myocardium. | 1989-06-20 |
|
| Does the positive inotropic action of a novel cardiotonic agent, MCI-154, involve mechanisms other than cyclic AMP? | 1987-11 |
|
| Stimulation of myocardium during reperfusion injury by a new inotrope-vasodilator agent, MCI-154. | 1987 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
474941-42-9
Created by
admin on Mon Mar 31 22:12:26 GMT 2025 , Edited by admin on Mon Mar 31 22:12:26 GMT 2025
|
PRIMARY | |||
|
WB65Y3B8VX
Created by
admin on Mon Mar 31 22:12:26 GMT 2025 , Edited by admin on Mon Mar 31 22:12:26 GMT 2025
|
PRIMARY | |||
|
9906730
Created by
admin on Mon Mar 31 22:12:26 GMT 2025 , Edited by admin on Mon Mar 31 22:12:26 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
